Newspaper Publication - Results Q4/ 2025-26 Board Meeting dated 14th May, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eiko Lifesciences has published its audited financial results for Q4 and the full year ended 31 March 2025 in Mumbai Lakshadweep (Marathi) and Financial Express (English), following board approval on 14 May 2025. On a standalone basis, full-year FY25 total income rose to ₹3,351.58 lakh from ₹2,810.54 lakh in FY24, while net profit after tax jumped to ₹174.08 lakh from ₹117.33 lakh, with basic EPS improving to ₹1.4 from ₹0.81. For Q4 FY25 standalone, net profit after tax climbed sharply to ₹90.19 lakh from ₹28.48 lakh a year earlier, even as revenue was largely flat at around ₹761.79 lakh. This is the first year the company is reporting consolidated results, which include subsidiary Eike Scientific Solutions LLP, subsidiary Eikovivify Logistics Pvt Ltd, and associate Reflux Pharmaceuticals Pvt Ltd; consolidated FY25 revenue stood at ₹3,838.01 lakh with net profit of ₹217.53 lakh.
The sharply higher Q4 profit and improvement in full-year earnings are positive signals for shareholders, though the standalone revenue base remains modest and growth was driven more by margin expansion than topline. First-time consolidated reporting brings added visibility into the group's broader performance.